Biologic interventions for fatigue in rheumatoid arthritis

Area of Science:

• Rheumatology
• Pharmacology
• Clinical Trials

Background:

• Fatigue is a prevalent and distressing symptom in rheumatoid arthritis (RA) lacking evidence-based management guidelines.
• Biologic interventions are known to improve RA symptoms, signs, and joint damage.

Purpose of the Study:

• To systematically evaluate the impact of biologic interventions on fatigue experienced by rheumatoid arthritis patients.

Main Methods:

• A comprehensive literature search was conducted across multiple electronic databases up to April 2014.
• Included were randomized controlled trials (RCTs) assessing biologic interventions for RA with self-reported fatigue as an outcome.
• Data from 32 RCTs involving 9946 participants in intervention groups and 4682 in control groups were meta-analyzed.

Main Results:

• Biologic agents demonstrated a statistically significant reduction in fatigue, with a standardized mean difference of -0.43 (95% CI -0.38 to -0.49).
• Both anti-tumor necrosis factor (anti-TNF) and non-anti-TNF biologics yielded similar fatigue improvements, equivalent to 6.3-6.9 units on the FACIT-F scale.
• The quality of included RCTs was moderate, with a low to unclear risk of bias in fatigue outcome reporting; long-term fatigue changes were not assessed.

Conclusions:

• Biologic interventions provide a small to moderate improvement in fatigue for active RA patients.
• The magnitude of fatigue improvement is comparable between anti-TNF and non-anti-TNF biologic agents.
• The precise mechanism (direct effect vs. indirect reduction of inflammation/disease activity) of biologics on fatigue remains unclear.